文献速递系统性红斑狼疮

多基因风险评分可预测台湾人群成人系统性红斑狼疮的早发及首年肾脏病变

Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort.
PubMed 文献 · RMD Open · 2024-04-18

在台湾人群中,基于27个SNP的C+T法SLE-PRS在训练集预测SLE易感性的AUC为0.629、测试集为0.620;最高四分位组较最低四分位组SLE发病更早、SLEDAI评分更高,且诊断首年内肾脏受累及血清学阳性风险升高。作者认为将PRS整合入临床决策可能有助于狼疮肾炎筛查和早期治疗。

要点

  • C+T法SLE-PRS仅纳入27个SNP,训练集AUC为0.629,优于Lassosum、PRSice-2、LDpred2和PRS-CS。
  • 最高PRS四分位组较最低四分位组SLE发病更早(39.06 vs 44.22岁,p<0.01),SLEDAI评分更高(3.00 vs 2.37,p=0.04)。
  • 最高PRS四分位组诊断首年内WHO III-IV型狼疮肾炎风险升高(OR 2.36,95%CI 1.47至3.80,p<0.01)。

核心结论

  • SLE的PRS与台湾患者发病更早、SLE诊断首年内肾脏受累及血清学阳性相关。
  • 作者认为将PRS整合入临床决策可能有助于狼疮肾炎筛查和早期治疗,以改善SLE患者的肾脏结局。

研究设计与样本

  • 研究纳入SLE患者2782例和匹配的非SLE对照11128例,采用Genome-Wide TWB 2.0单核苷酸多态性(SNP)芯片进行基因分型。
  • 构建C+T、LDpred2、Lassosum、PRSice-2和PRS-连续收缩(PRS-CS)等多种PRS模型预测SLE易感性,并用逻辑回归评估基于C+T的PRS与SLE患者肾脏受累的关联。

主要发现

  • 训练集中基于C+T的SLE-PRS仅纳入27个SNP,AUC为0.629,高于Lassosum(AUC=0.621)、PRSice-2(AUC=0.615)、LDpred2(AUC=0.609)和PRS-CS(AUC=0.602)。
  • 基于C+T的SLE-PRS在测试集中预测能力一致(AUC=0.620)。
  • 最高四分位组较最低四分位组SLE发病更早(39.06 vs 44.22岁,p<0.01),SLEDAI评分更高(3.00 vs 2.37,p=0.04)。
  • 最高四分位组较最低四分位组SLE诊断首年内肾脏受累风险升高:WHO III-IV型狼疮肾炎OR 2.36(95%CI 1.47至3.80,p<0.01),估算肾小球滤过率<60 mL/min/1.73m2的OR 1.49(95%CI 1.18至1.89,p<0.01),尿蛋白与肌酐比值>150 mg/day的OR 2.07(95%CI 1.49至2.89,p<0.01)。
  • 最高四分位组较最低四分位组血清学阳性风险升高;在发病年龄<50岁的SLE患者中,最高PRS四分位与诊断首年内更严重的肾脏疾病显著相关。

关键数值与推荐

  • C+T法SLE-PRS训练集AUC=0.629,测试集AUC=0.620。
  • 最高四分位组WHO III-IV型狼疮肾炎OR 2.36(95%CI 1.47至3.80,p<0.01)。
  • 最高四分位组估算肾小球滤过率<60 mL/min/1.73m2的OR 1.49(95%CI 1.18至1.89,p<0.01)。
  • 最高四分位组尿蛋白与肌酐比值>150 mg/day的OR 2.07(95%CI 1.49至2.89,p<0.01)。

临床怎么用

  • 作者认为将PRS整合入临床决策可能有助于狼疮肾炎筛查和早期治疗,以改善SLE患者的肾脏结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to develop a predictive model using polygenic risk score (PRS) to forecast renal outcomes for adult systemic lupus erythematosus (SLE) in a Taiwanese population. METHODS: Patients with SLE (n=2782) and matched non-SLE controls (n=11 128) were genotyped using Genome-Wide TWB 2.0 single-nucleotide polymorphism (SNP) array. PRS models (C+T, LDpred2, Lassosum, PRSice-2, PRS-continuous shrinkage (CS)) were constructed for predicting SLE susceptibility. Logistic regression was assessed for C+T-based PRS association with renal involvement in patients with SLE. RESULTS: In the training set, C+T-based SLE-PRS, only incorporating 27 SNPs, outperformed other models with area under the curve (AUC) values of 0.629, surpassing Lassosum (AUC=0.621), PRSice-2 (AUC=0.615), LDpred2 (AUC=0.609) and PRS-CS (AUC=0.602). Additionally, C+T-based SLE-PRS demonstrated consistent predictive capacity in the testing set (AUC=0.620). Individuals in the highest quartile exhibited earlier SLE onset (39.06 vs 44.22 years, p<0.01), higher Systemic Lupus Erythematosus Disease Activity Index scores (3.00 vs 2.37, p=0.04), elevated risks of renal involvement within the first year of SLE diagnosis, including WHO class III-IV lupus nephritis (OR 2.36, 95% CI 1.47 to 3.80, p<0.01), estimated glomerular filtration rate <60 mL/min/1.73m2 (OR 1.49, 95% CI 1.18 to 1.89, p<0.01) and urine protein-to-creatinine ratio >150 mg/day (OR 2.07, 95% CI 1.49 to 2.89, p<0.01), along with increased seropositivity risks, compared with those in the lowest quartile. Furthermore, among patients with SLE with onset before 50 years, the highest PRS quartile was significantly associated with more serious renal diseases within the first year of SLE diagnosis. CONCLUSIONS: PRS of SLE is associated with earlier onset, renal involvement within the first year of SLE diagnosis and seropositivity in Taiwanese patients. Integrating PRS with clinical decision-making may enhance lupus nephritis screening and early treatment to improve renal outcomes in patients with SLE.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Chen YJ, Hsiao TH, Lin YC, et al. Polygenic Risk Score Predicts Earlier-Onset Adult Systemic Lupus Erythematosus and First-Year Renal Diseases in a Taiwanese Cohort. RMD Open. 2024. PMID: 38637112. doi:10.1136/rmdopen-2023-003293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。